TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00089609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 intravenously over 60 minutes on cycle 1 day 1 repeated every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 intravenously over 60 minutes on cycle 1 day 1 repeated every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 200 mg by mouth daily throughout the cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 200 mg by mouth daily throughout the cycle.
Study: NCT04293081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preemptive chlorepheniramine maleate intravenous injection
Description: Participants of group A will receive only one ampoule of 45.5 mg/ 2mL chlorepheniramine maleate diluted in 8 ml isotonic saline intravenous (I.V) prior to induction of general anesthesia by 30 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: participants in group (B) will receive 10 ml isotonic saline (placebo) by the same route as control.
Study: NCT01741285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone (QVAR)
Description: Small particle treatment
Study: NCT00089609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 10 mg by mouth daily throughout the cycle.
Study: NCT01741285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone (QVAR)
Description: Small particle treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone (Clenil)
Description: Course particle beclomethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone (Clenil)
Description: Course particle beclomethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: Course particle treatment
Study: NCT02806115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acetic acid-enhanced endoscopy
Description: Acetic acid-enhanced endoscopy combines conventional endoscopy with the instillation of acetic acid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetic Acid
Description: The concentration of acetic acid used in this study is 1.5%.
Study: NCT02806115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endoscope
Description: This study using an EG-29-i10 endoscope (Pentax, Tokyo, Japan) and an EPK-i7010 processor (Pentax, Tokyo, Japan).
Study: NCT01188512

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPZE1
Description: Individuals will be vaccinated once intranasally with the designated dose of BPZE1 Dose 2 x 0.1 mL (0.1 mL per nostril).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPZE1
Description: Individuals will be vaccinated once intranasally with the designated dose of BPZE1 Dose 2 x 0.1 mL (0.1 mL per nostril).
Study: NCT00089609

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab 15 mg/kg intravenously on cycle 1 day 1 every 21 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab 15 mg/kg intravenously on cycle 1 day 1 every 21 days.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Two buffy coat tubes (two 7mL blue tiger top tubes) will be obtained and wrapped in foil when the patient enters onto the study. DNA (deoxyribonucleic acid) will be isolated only for the purpose of genotype analysis of enzymes with putative relevance for docetaxel or thalidomide disposition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: The PBMC (peripheral blood mononuclear cells) of patients will be analyzed pre-treatment and post cycle 2 for any changes in the function of regulatory T cells. The following analysis will be performed: flow cytometry analysis, CD4 CD25 T cell enrichment, and immunosuppression assay.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Serum and urine samples will be collected at baseline and monthly to measure VEGF (vascular endothelial growth factor) levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Plasma concentrations of docetaxel and thalidomide will be determined to assess interactions between docetaxel (and thalidomide) and the concomitant therapy.The analysis will be performed using a validated method based on liquid chromotography with mass-spectrometric detection.
Study: NCT01188512

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPZE1
Description: Individuals will be vaccinated once intranasally with the designated dose of BPZE1 Dose 2 x 0.1 mL (0.1 mL per nostril).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Individuals will get placebo once intranasally. Dose 2 x 0.1 mL (0.1 mL per nostril).
Study: NCT02795247

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cruciate Ligament Reconstruction
Study: NCT02643368

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mOPV2 at 6 and 7 weeks of age
Description: Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 7 weeks of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mOPV2 at 6 and 8 weeks of age
Description: Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 8 weeks of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mOPV2 at 6 and 10 weeks of age
Description: Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 10 weeks of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mOPV2 at 6 and 10 weeks of age
Description: Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 10 weeks of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV at 6 weeks of age
Description: Participants assigned to this intervention will receive a dose of inactivated polio vaccine (IPV) 6 weeks of age
Study: NCT03337022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90006
Description: CC-90006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90006
Description: CC-90006
Study: NCT02795247

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cruciate Ligament Reconstruction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cruciate Ligament Reconstruction
Study: NCT00702988

Intervention type: DRUG
Intervention: Org 36286
Description: single dose of 60, 120, or 180 μg Org 36286 (experimental group administered under protocol 38826)

Intervention type: DRUG
Intervention: recFSH
Description: 150 IU recFSH daily (reference group administered under protocol 38826)
Study: NCT00717288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir
Description: Detemir dosed at 50% of calculated basal insulin infusion requirements

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir
Description: Detemir dosed at 65% of calculated basal insulin infusion requirements

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir
Description: Detemir dosed at 80% of calculated basal insulin infusion requirements
Study: NCT02995408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Response Resiliency Program for Parents of Children with ASD
Study: NCT03337022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90006
Description: CC-90006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90006
Description: CC-90006

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01452867

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bag-Valve-Mask-Ventilation (Ambu Facemask)
Description: Bag-Valve Mask-Ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask (Laryngeal Mask Airway Supreme)
Description: Ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Tube (Laryngeal Tube LT-S-D (VBM))
Description: Ventilation
Study: NCT04918394

Intervention type: OTHER
Intervention: Questionnaire of Mold / moisture exposure
Description: Mold / moisture exposure is assessed by the 5 following questions, whose positive response has been associated with the actual presence of mold in the household (according to data from the literature data), asked in the form of a parent-completed declarative questionnaire regarding the child's primary living home:~* Presence of visible mold~* Impression of dampness~* Apparent dampness~* Existence of recent water damage in the last year~* Presence of a moldy odor

Intervention type: OTHER
Intervention: Questionnaire of Mold / moisture exposure
Description: Mold / moisture exposure is assessed by the 5 following questions, whose positive response has been associated with the actual presence of mold in the household (according to data from the literature data), asked in the form of a parent-completed declarative questionnaire regarding the child's primary living home:~* Presence of visible mold~* Impression of dampness~* Apparent dampness~* Existence of recent water damage in the last year~* Presence of a moldy odor
Study: NCT01366976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 1g every 6 hours for 4 doses over 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 1g every 6 hours for 4 doses over 24 hours
Study: NCT01181115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avonex
Description: Interferon treatment for MS
Study: NCT04552457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No activity restrictions
Description: Patients in the No activity restrictions group will be allowed to return to their normal activity immediately.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activity restrictions
Description: Patients in the Activity restrictions group will not be allowed to perform strenuous exercise or lift anything greater than 10lbs. Strenuous exercise will be defined as is any activity that requires so much exertion that one cannot have a conversation comfortably while doing it.
Study: NCT03482102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab target the cancerous proteins and stop the cancer cells from suppressing the immune system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab target the cancerous proteins and stop the cancer cells from suppressing the immune system
Study: NCT01741285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: Course particle treatment
Study: NCT03482102

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy is used to shrink cancer cells.
Study: NCT04540926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: COVID-19 pneumonia patients treated with oral CsA at a dose of 1-2 mg /kg / day divided into two doses, for 7 days, since entering to hospitalization.
Study: NCT03055598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Citrate
Description: Doses can be adjusted as needed by 1 to 2 tablets up to a maximum of 12 tablets daily. Dose can be titrated at 1-week or longer intervals.
Study: NCT04330612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perioperative Updates
Description: In the intervention group, the families received additional standardized electronic updates via pagers at three pivotal moments: 1) Initial skin incision has been made; 2) Critical part of the case is completed and closure has begun; and, 3) Closure is complete, and patient will be transferred to the recovery room when ready.
Study: NCT02051218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab (reduced dosing)
Description: 3x Denosumab 120mg (XGEVA®) sc. q4w followed by Denosumab 120mg (XGEVA®) sc. q12w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab (standard dosing)
Description: Denosumab 120mg (XGEVA®) sc. q4w
Study: NCT03266432

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: three blood samples : first one pre intervention and the other two blood samples post-intervention
Study: NCT02132039

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12-step sitting Tai Chi Chuan
Description: The intervention consists of eight home-based sessions on 12-step sitting Tai Chi Chuan. Each session will last for an hour.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control consists of eight home-based sessions on useful health-care information. Each session will last for an hour.
Study: NCT00650169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel Bisulfate Tablets 75 mg
Description: 75mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plavix® Tablets 75 mg
Description: 75mg, single dose fed
Study: NCT03830320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [64Cu]FBP8
Description: Injection of Copper-64 radiopeptide to detect thrombosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [64Cu]FBP8
Description: Injection of Copper-64 radiopeptide to detect thrombosis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [64Cu]FBP8
Description: Injection of Copper-64 radiopeptide to detect thrombosis
Study: NCT03437811

Intervention type: DEVICE
Intervention: Electro Flo Percussor, Model 5000
Description: FDA 510K K031876 Regulation Number: 21 CFR 868.5665 Regulation Name: Percussor, Powered-Electric Regulation Class: II Product Code: BY1
Study: NCT03715036

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point-of-care US
Description: The intervention includes reassuring the AC and DVP
Study: NCT02053649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Triple Chronotherapy
Description: triple chronotherapy (TC will consist of bright light therapy, sleep phase advance, and sleep deprivation/restriction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: UC will consist of medication administered by a perinatal psychiatrist and/or psychotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: UC will consist of medication administered by a perinatal psychiatrist and/or psychotherapy
Study: NCT02367690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Topical gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Topical gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Topical gel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard-of-Care
Description: Surgical debridement, sterile saline rinses, and dressing changes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard-of-Care
Description: Surgical debridement, sterile saline rinses, and dressing changes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard-of-Care
Description: Surgical debridement, sterile saline rinses, and dressing changes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle Gel
Description: Topical vehicle gel with no active ingredients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle Gel
Description: Topical vehicle gel with no active ingredients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle Gel
Description: Topical vehicle gel with no active ingredients.
Study: NCT03523390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 3 mg/kg Q2W
Description: Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 3 milligrams per kilogram (mg/kg) once every 2 weeks (Q2W) until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg Q2W
Description: Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg Q2W until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 20 mg/kg Q2W
Description: Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 20 mg/kg Q2W until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg QW
Description: Participants received intravenous infusion of Avelumab over 1 hour duration at a dose of 10 mg/kg every week (QW) for the first 12 weeks followed by once every 2 weeks, started at Week 13 until disease progression, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the study or from Avelumab occurs.
Study: NCT02527291

Intervention type: OTHER
Intervention: Blood test
Description: Blood test for CMV PCR and IL28

Intervention type: OTHER
Intervention: Blood test
Description: Blood test for CMV PCR and IL28

Intervention type: OTHER
Intervention: Blood test
Description: Blood test for CMV PCR and IL28
Study: NCT03914924

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: On-site delivery: The supervised exercise sessions will be offered twice a week from the first to fourth weeks and once a week from the fifth week onwards. Each session lasts approximately 60 minutes.~Remote delivery: The participants will attend an initial supervised exercise session delivered on-site. After this session, they will receive the exercise intervention through a website specific to the Ex program. Participants will receive weekly WhatsApp messages to remind them about the exercise routine.~Independent of the delivery format all participants will receive counseling to accumulate at least 150 min of aerobic exercise per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: On-site delivery: The supervised exercise sessions will be offered twice a week from the first to fourth weeks and once a week from the fifth week onwards. Each session lasts approximately 60 minutes.~Remote delivery: The participants will attend an initial supervised exercise session delivered on-site. After this session, they will receive the exercise intervention through a website specific to the Ex program. Participants will receive weekly WhatsApp messages to remind them about the exercise routine.~Independent of the delivery format all participants will receive counseling to accumulate at least 150 min of aerobic exercise per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Education Program
Description: On-site delivery: The supervised exercise sessions will be offered twice a week from the first to fourth weeks and once a week from the fifth week onwards. Each session will last approximately 60 minutes. Participants will receive a printed version of the Diabetes College Guide containing twenty chapters and they will attend eighteen thirty-minute education classes.~Remote delivery: The participants will attend an initial supervised exercise session delivered on-site. After this session, they will receive the interventions (exercise and education) through a website specific to the ExLE program. Participants will receive a printed version of the Diabetes College Guide, as well as, guidance on accessing the educational content on the website and weekly WhatsApp messages with reminders about educational content scheduled for that week.~Independent of the delivery format all participants will receive counseling to accumulate at least 150 min of aerobic exercise per week.
Study: NCT02967042

Intervention type: DEVICE
Group type: OTHER
Intervention: 18F-PET-TT
Description: can 18F-PET-TT be used as an diagnostic tool in patients with CKD-MBD
Study: NCT02948452

Intervention type: OTHER
Intervention: fMRI
Description: fMRI: reward task, anxiety provocation

Intervention type: OTHER
Intervention: fMRI
Description: fMRI: reward task, anxiety provocation
Study: NCT03373006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axumin PET/CT
Description: Synthetic amino acid uptake agent injection followed by imaging
Study: NCT03775473

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: progastrin
Description: PROCODE is an interventional study of category 2 (non-medicinal product), with a minimal risks and restrictions, involving only one blood drawn at the screening of colon cancer.
Study: NCT02935010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: proton pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: proton pump inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: Gastric mucosal protective drug with anti-H. pylori effect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: antibiotic for H. pylori eradication
Study: NCT02026193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oocyte vitrification

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: embryo freezing
Study: NCT02565303

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervertebral space

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervertebral space

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: The initial dose of ropivacaine is chosen as 12 mg in L2-3 group and 15 mg in L3-4 group with the volume of 3 mL in both groups. The testing interval is 0.5 mg with subsequent doses being determined by the outcome of the previous injection in the same group.If the previous response is ineffective, the next patient will receive 0.5 mg more than the last patient. If the response of the previous patient is effective, the next patient decrease 0.5mg.